Aptose Biosciences (NASDAQ:APTO) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report sent to investors on Tuesday,Benzinga reports. They currently have a $2.00 price objective on the biotechnology company’s stock.

Separately, StockNews.com initiated coverage on shares of Aptose Biosciences in a report on Friday, November 29th. They issued a “hold” rating for the company.

Aptose Biosciences Trading Up 1.5 %

APTO opened at $0.19 on Tuesday. The company has a market capitalization of $3.38 million, a price-to-earnings ratio of -0.06 and a beta of 1.06. Aptose Biosciences has a 12-month low of $0.13 and a 12-month high of $2.91. The business’s fifty day simple moving average is $0.35 and its 200-day simple moving average is $0.55.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC purchased a new position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned about 9.46% of Aptose Biosciences at the end of the most recent quarter. 26.62% of the stock is currently owned by hedge funds and other institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.